Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Provectus Pharmaceuticals, Inc. (PVCT-OCT: BB) |
|
|
We have solved the essential problem that other scientists and companies have not been able to solve; that is to make a cancer specific drug. We have found out how to make it simply, pragmatically and inexpensively; namely, to build it and make a very safe molecule. - Dr. H. Craig Dees, Ph.D. (PVCT) (Interview published April 12, 2007) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Provectus News PV-10 for Melanoma
Clinical Trial Gaining Media Attention
The positive PV-10 for melanoma Phase 2 clinical trial data presented at ASCO 2010, including encouraging data on visceral metastases, has gained the attention of several prominent medical trade outlets. The following articles are available for viewing online:
Doctor's Guide Channels
Medical News Today
Skin & Aging
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.